Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856114 · ClinicalTrials.gov registry record · Phase 2
Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01856114: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01856114 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01856114, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if fentanyl can change perception of shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly used for treatment of cancer pain. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Fentanyl Buccal Tablet
- OTHER Placebo Buccal Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2019-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01856114
The ClinicalTrials.gov registry entry for NCT01856114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaires is the first listed.
NCT01856114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01856114 about?
NCT01856114 is a clinical study titled "Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea". The goal of this clinical research study is to learn if fentanyl can change perception of shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function. In this study, fentanyl will be compared to a placebo. Fentanyl is commonly ...
What is the current status of trial NCT01856114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-05-27. Estimated completion is 2019-12-04.
What interventions are being tested in trial NCT01856114?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Fentanyl Buccal Tablet (DRUG), Placebo Buccal Tablet (OTHER).
Who is sponsoring clinical trial NCT01856114?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.